You are here: Industry Insights > A1C

News List

Lilly's SURPASS-1 results published in The Lancet show tirzepatide's superior A1C and body weight reductions versus placebo in adults with type 2 diabetes firstwordpharma
June 28, 2021
Tirzepatide led to superior A1C and body weight reductions from baseline across all three doses in adults with type 2 diabetes after 40 weeks of treatment in Eli Lilly and Company's (NYSE: LLY) SURPASS-1 monotherapy clinical trial evaluating the efficacy
America Is Losing the War Against Diabetes drugs
June 11, 2021
After years of improvement, Americans with diabetes may be losing some ground in controlling the condition, a new government-funded study shows.
Lilly’s tirzepatide achieves superior A1C reductions versus insulin glargine pharmatimes
May 25, 2021
Eli Lilly’s investigational candidate tirzepatide achieved superior A1C and body weight reductions compared with insulin glargine in adults with type 2 diabetes who have increased cardiovascular risk.
Lilly's Tirzepatide Reduced A1C, Body Weight for Type 2 Diabetes americanpharmaceuticalreview
December 10, 2020
Tirzepatide led to superior A1C and body weight reductions from baseline in adults with type 2 diabetes after 40 weeks of treatment in topline results from Eli Lilly and Company's SURPASS-1 monotherapy clinical trial evaluating the efficacy and safety ...
Keeping Blood Sugar Steady Helps You Live Longer With Diabetes drugs
September 20, 2019
Keeping your blood sugar levels stable over time may be key to living longer if you have type 2 diabetes.
Tight Diabetes Control Alone May Not Benefit the Heart Long-Term drugs
June 06, 2019
Tight Diabetes Control Alone May Not Benefit the Heart Long-Term.